Photodynamic therapy in neurosurgery: A review

Journal of Photochemistry and Photobiology B: Biology

Volumn 36, Issue 2, 1996, Pages 157-168

  Kostron, Herwig ^a   Obwegeser, Alois ^a   Jakober, Rosanna ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cerebral malignancies; Haematoporphyrin derivative; Photodynamic therapy

Indexed keywords

HEMATOPORPHYRIN DERIVATIVE; PHOTOFRIN I; PHOTOFRIN II; PHOTOSAN; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

BRAIN BIOPSY; BRAIN TUMOR; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTRACRANIAL PRESSURE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NEUROSURGERY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOOXIDATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR BIOPSY;

BIOPSY; BRAIN; BRAIN NEOPLASMS; GLIOBLASTOMA; HEMATOPORPHYRIN DERIVATIVE; HUMANS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEUROSURGERY; PHOTOCHEMOTHERAPY;

EID: 0030294844     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1011-1344(96)07364-2     Document Type: Conference Paper

References (115)

1. [1] A. Obwegeser, M. Ortler, M. Seiwald, H. Ulmer and H. Kostron, Glioblastoma multiformae: an accumulated experience over 10 years, Acta Neurochir., 137 (1995) 29-33.
2. [2] W.R. Shapiro, S.B. Green, P.C. Burger, M.St. Mahaley and R.G. Selker, Brain tumour cooperative group trial 8001, J. Neurosurg., 71 (1989) 1-12.
3. [3] M.T. Foultier, T. Patrice, Y. Yactayo, Y. Lajat and F. Resche, Photodynamic treatment of normal endothelial cells or glioma cells in vitro, Surg. Neurol., 37 (1992) 83-88.
4. [4] J.S. Hill, S.B. Kahl, A.H. Kaye, S.S. Stylli,M.S. Koo, M.F. Gonzales, N.J. Vardaxis and C.I. Johnson, Selective tumour uptake of a boronated porphyrin in an animal model of cerebral glioma, Proc. Natl. Acad. Sci. USA, 89 (1992) 1785-1789.
5. [5] Y. Ji, D. Walstad, J.T. Brown and S.K. Powers, Improved survival from intracavitary photodynamic therapy of rat glioma, Photochem. Photobiol., 56 (1992) 385-390.
6. [6] K.W. Woodburn, S. Stylli, J.S. Hill, A.H. Kaye, J.A. Reiss and D. Phillips, Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy, Br. J. Cancer, 65 (1992) 321-328.
7. [7] E.H. Oldfield, Z. Ram, K.W. Culver, R.M. Blase, H.L. DeVroom and W.F. Anderson, Gene therapy for the treatment of brain tumours using intra-tumoral transduction with the thymidine kinase gene and intravenous gancoclovir, Hum. Gene Ther., 4 (1993) 39-69.
8. [8] P. Riva, A. Arista, C. Sturiale, G. Franceschi, A. Spinelli, N. Riva, M. Casi, G. Moscatelli and M. Frattarelli, Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumours, Cancer, 173 (1994) 1076-1082.
9. [9] C.T. Perria, T. Capuzzo and G. Cavagnaro, First attempts at the photodynamic treatment of human gliomas, J. Neurosurg. Sci., 24 (1980) 119-129.
10. [10] D.P. Noske, J.G. Wolbers and H.J. Sterenborg, Photodynamic therapy of malignant glioma, A review of literature, Clin. Neurol. Neurosurg., 95 (1991) 293-307.
11. [11] H.I. Pass, Review, photodynamic therapy in oncology: mechanisms and clinical use, J. Natl. Cancer Inst., 85 (1993) 443-456.
12. [12] R. Van Hillegersberg, W.J. Kort and J.H.P. Wilson, Current status of photodynamic therapy in oncology, Drugs, 48 (1994) 510-527.
13. [13] S.H. Kaneko, Y. Kobayashi and Y. Kohama,Stereotactic intratumoral photodynamic therapy on malignant brain tumours, International Symposium on Photodynamic Therapy in Clinical Practice, Innsbruck, 1995, Abstract.
14. [14] A.H. Kaye and J.S. Hill, Photodynamic therapy of brain tumours, Ann. Acad. Med. Singapore, 22 (1993) 470-481.
15. [15] H. Kostron, B.W. Hochleitner, A. Obwegeser and M. Seiwald, Clinical and experimental results of photodynamic therapy in neurosurgery, SPIE Proc., 2371 (1995) 126-128.
16. [16] Y. Layat and T. Patrice, Photochemotherapy applied stereotactically to brain tumours, Surg. Neurol., 27 (1987) 403-404.
17. [17] P.J. Muller and B.C. Wilson, Photodynamic therapy of malignant brain tumours, Can. J. Neurol Sci., 17 (1990) 193-198.
18. [18] P.J. Muller and B.C. Wilson, Photodynamic therapy of malignant primary brain tumours: clinical effects, post-operative ICP, and light penetration of the brain, Photochem. Photobiol., 46 (1987) 929-935.
19. [19] T.C. Origitano, M.J. Caron and O.H. Reichman, Photodynamic therapy for intracranial neoplasms. Literature review and institutional experience, Mol. Chem. Neuropathol., 21 (1994) 337-352.
20. [20] C. Perria, M. Carai, A. Falzoi, G. Orunesu, A. Rocca, G. Massarelli, N. Francaviglia and G. Jori, Photodynamic therapy of malignant brain tumours: clinical results of, difficulties with, questions about, and future prospects for the neurosurgical applications, Neurosurgery, 23 (1988) 557-563.
21. [21] S.K. Powers, S.S. Cush, D.L. Walstad and L. Kwock, Stereotactic intratumoral photodynamic therapy for recurrent malignant brain tumours, Neurosurgery, 29 (1991) 688-695.
22. [22] D.R. Sandeman, Photodynamic therapy in the management of maligant gliomas: a review, Lasers Med. Sci., 1 (1986) 163-174.
23. [23] J. Denekamp, Inadequate vasculature in solid tumours: consequences for cancer research strategies, BJR Suppl., 24 (1992) 111-117.
24. [24] J.L. Evelhoch, J.B. McDougall, J. Mattiello and N.E. Simpson, Measurement of relative regional tumour blood flow in mice by deuterium NMR imaging, Magn. Reson. Med., 24 (1992) 42-52.
25. [25] J.V. Moore, C.M. West and A.K. Haylett, Vascular function and tissue injury in murine skin following hyperthermia and photodynamic therapy, alone and in combination, Br. J. Cancer, 66 (1992) 1037-1043.
26. [26] H. Kostron, G. Weiser, E. Fritsch and V. Grunert, Photodynamic therapy of malignant brain tumours: clinical and neuropathological results, Photochem. Photobiol., 46 (1987) 937-943.
27. [27] A. Segalla, C. Milanesi, G. Jori, H.G. Capraro, U. Isele and K. Schieweck, CGP 55398, a liposomal Ge(IV) phthalocyanine bearing two axially ligated cholesterol moieties: a new potential agent for photodynamic therapy of tumours, Br. J. Cancer, 69 (1994) 817-825.
28. [28] H. Fukuda, S. Paredes and A.M. Battle, Tumour-localizing properties of porphyrins. In vitro studies using the porphyrin precursor, aminolevulinic acid, in free and liposome encapsulated forms, Drug Des. Deliv., 5 (1989) 133-139.
29. [29] M.W. Leach, S. Khoshyomn, J. Bringus, S.A. Autry and J.E. Boggan, Normal brain tissue response to photodynamic therapy using aluminum phthalocyanine tetrasulfonate in the rat, Photochem. Photobiol, 57 (1993) 842-845.
30. [30] L. Morgan, H. Lottman, C.C. Abbou and D.K. Chopin, A comparison of direct and liposomal antibody conjugates of sulfonated aluminum phthalocyanines for selective photoimmunotherapy of human bladder carcinoma, Photochem. Photobiol., 60 (1994) 486-496.
31. [31] L. Morlet, V. Vonarx-Coinsman, P. Lenz, M.T. Foultier, L.X. de Brito, C. Stewart and T. Patrice, Correlation between meso(tetra-hydroxyphenyl)chlorine (m-THPC) biodistribution and photodynamic effects in mice, J. Photochem. Photobiol. B: Biol., 28 (1995) 25-32.
32. [32] Q. Peng, J. Moan, L.W. Ma and J.M. Nesland, Uptake, localization and photodynamic effect of meso-tetra(hydroxyphenyl)porphine and its corresponding chlorin in normal and tumour tissues of mice bearing mammary carcinoma, Cancer Res., 55 (1995) 2602-2626.
33. [33] A. Obwegeser and H. Kostron, in preparation.
34. [34] B. A. Allison, P.H. Pritchard and J.G. Levy, Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative, Br. J. Cancer, 69 (1994) 833-839.
35. [35] I. Fujishima, T. Sakai, T. Tanaka, H. Ryu, K. Uemura, Y. Fujishima, K. Horiuchi, N. Daikuzono and Y. Sekiguchi, Photodynamic therapy using pheophorbide a and Nd: YAG laser, Neurol Med. Chir. Tokyo, 31 (1991) 257-263.
36. [36] A.W. Hemming, N.L. Davis, B. Dubois, N.F. Quenville and R.J. Finley, Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate, Surg. Oncol., 2 (1993) 187-196.
37. [37] Y.S. Lee and R.D. Wurster, Methylene blue induces cytotoxicity in human brain tumour cells, Cancer Lett., 88 (1995) 141-145.
38. [38] H. Lui, Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update, Sem. Oncol., 21 (1994) 11-14.
39. [39] U. Schmidt-Erfurth, T. Hasan, T. Flotte, E. Gradoudas and R. Birngruber, Photodynamic therapy of experimental, intraocular tumours with benzoporphyrin-lipoprotein, Ophthalmologie, 91 (1994) 348-356.
40. [40] K.W. Woodburn, J.S. Hill, S. Stylli, A.H. Kaye, J.A. Reiss and D.R. Phillips, Evaluation of a morpholinothiolporphyrin for use in photodynamic therapy, Br. J. Cancer, 70 (1994) 398-400.
41. [41] M. Athar, C.A. Elmets, D.R. Bickers and H. Mukthtar, A novel mechanism for the generation of superoxide anions in hematoporphyrin derivative-mediated cutaneous photosensitization. Activation of the xanthine oxidative pathways, J. Clin. Invest., 83 (1989) 1137-1143.
42. [42] T.J. Dougherty and S.L. Marcus, Photodynamic therapy: new approaches, Sem. Surg. Oncol., 5 (1989) 6-16.
43. [43] L.I. Grossweiner, A.S. Pate and J.B. Grossweiner, Type I and type II mechanisms in the photosensitized lysis of phosphatidylcholine liposomes by hematoporphyrin, Photochem. Pholobiol., 36 (1982) 159-167.
44. [44] V.H. Fingar, T.J. Weiman, Y.J. Park and B.W. Hendersen, Implications of a pre-existing tumour hypoxic fraction on photodynamic therapy, J. Surg. Res., 53 (1992) 524-528.
45. [45] S. Hotta, H. Kashimura, S, Hirai, A. Nakahara, F. Fukutomi, T. Osuga and Y. Uchiyama, Immediate changes in subcellular structures of transplanted tumours following photodynamic and laser hyperthermic therapy, Lasers Surg. Med., 16 (1995) 262-271.
46. [46] M.R. Hamblin and E. Newman, On the mechanism of the tumour-localising effect in photodynamic therapy, J. Photochem. Pholobiol. B: Biol., 23 (1994) 3-8.
47. [47] G. Krosl, M. Korbelik and G.J. Dougherty, Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy, Br. J. Cancer, 71 (1995) 549-555.
48. [48] T.W. Chanwitayanuchit, W. Bernwick, G. Weiser, E. Fritsch, M. Maier and H. Kostrom, Neuropathological changes in normal rat brain after intravenous or direct injection of haematoporphyrin derivative (HPD) followed by combination of light and fast electron therapy, Asian J. Surg., 13 (1990) 32-36.
49. [49] K.M. Hebeda, J.B. Wolbers, H.J.C.M. Sterenborg, W. Kamohorst, J.J.C. van Gemert and H.A.M. van Alphen, Fluorescence localization in tumour and normal brain after intratumoral injection of haematoporphyrin derivative into rat brain tumour, J. Photochem. Photobiol. B: Biol., 27 (1995) 85-92.
50. [50] H. Kostron, M.R. Swarzt and R.L. Martuza, Co-60 and direct intraneoplastic injection of HPD enhances the effect of phototherapy, J. Neurooncol., 2 (1988) 185-191.
51. [51] J. Blais, C. Amirand, J.P. Ballini, P. Debey, M.T. Foultier and T. Patrice, Photofrin induced fluorescence in progressive and regressive murine colonic cancer cells: correlation with cell photosensitivity, J. Photochem. Pholobiol. B: Biol., 27 (1995) 225-231.
52. [52] M.T. Foultier, V. Vonarx-Coinsman, L.X. de-Brito, L. Morlet, N. Robillard and T. Patrice, DNA or cell kinetics flow cytometry analysis of 33 small gastrointestinal cancers treated by photodynamic therapy, Cancer, 73 (1994) 1595-1607.
53. [53] M. Chopp, Q. Chen, M.O. Dereski and F.W. Hetzel, Chronic metabolic measurements of normal brain tissue response to photodynamic therapy, Photochem. Photobiol., 52 (1990) 1033-1036.
54. 1H magnetic resonance imaging of normal brain tissue response to photodynamic therapy, Neurosurgery, 29 (1991) 538-546.
55. [55] D.A. Bellnier, Potentiation of photodynamic therapy in mice with recombinant human tumour necrosis factor-alpha, J. Photochem. Photobiol. B: Biol., 8 (1991) 203-210.
56. [56] R. Bianchi, A. Giampietri, F. Campanile, M.C. Fioretti and P. Puccetti, Experimental studies of immunotoxicity of a photosensitizing agent (Photofrin II) in mice, J. Chemother., 4 (1992) 290-296.
57. [57] W.H. Boehncke, K. Konig, R. Kaufmann, W. Scheffold, O. Prummer and W. Sterry, Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo, Arch. Dermatol. Res., 286 (1994) 300-303.
58. [58] M.A. Breider, X. Lu, M. Panjehpour and D.L. Frazier, Cytokine modulation of endothelial cell sensitivity to photodynamic therapy, Lasers Surg. Med., 13 (1993) 305-341.
59. [59] S. Evans, W. Matthews, R. Perry, D. Fraker, J. Norton and H.I. Pass, Effect of photodynamic therapy on tumour necrosis factor production by murine macrophages, J. Natl. Cancer Inst., 83 (1990) 34-39.
60. [60] G. Kick, G. Messer, A. Goetz, G. Plewig and P. Kind, Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding, Cancer Res., 55 (1995) 2373-2379.
61. [61] D.J. Riemann, M.A. Anzano, G.W. Chan, T.J. Imburgia, J.A. Chan, R.K. Johnson and R.G. Greig, Antagonism of TGF-alpha receptor binding and TGF-alpha induced stimulation of cell proliferation by methyl pheophorbides, Oncol. Res., 4 (1992) 193-200.
62. [62] M. Plattner, W. Bernwick and H. Kostron, HPD-PDT in vitro sensitivity testing for brain tumours, SPIE Proc., 1616 (1993) 182-185.
63. [63] M.C. Luna, S. Wong and C.J. Gomer, Photodynamic therapy mediated induction of early response genes, Cancer Res., 54 (5) (1994) 1374-1380.
64. [64] A. Ohira, O. Honda, C.D. Gauntt, M. Yamamoto, K. Hori, H. Masutani, J. Yodoi and Y. Honda, Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina, Lab. Invest., 70 (1994) 279-285.
65. [65] L.C. Penning, J.W. Lagerberg, J.H. VanDierendonck, C.J. Cornelisse, T.M. Dubbelman and I. Van Steveninck, The role of DNA damage and inhibition of poly(ADP-ribosyl)ation in loss of clonogenicity of murine L929 fibroblasts, caused by photodynamically induced oxidative stress, Cancer Res., 54 (1994) 5561-5567.
66. 2+ transport in monkey kidney cells (CV-1), Photochem. Photobiol., 60 (1994) 368-372.
67. 2+ influx induced by photodynamic action in human cerebral glioma (U-87 MG) cells: possible involvement of a calcium channel, Photochem. Photobiol., 60 (1994) 244-248.
68. [68] F.A.X. Schanne, A.B. Kane, E.E. Young and J.L. Farber, Calcium dependence of toxic cell death, a final common pathway, Science, 206 (1979) 700-702.
69. [69] P.C. De-Smidt, A.J. Versluis and T.J. Van-Berkel, Properties of incorporation, redistribution, and integrity of porphyrin-low-density lipoprotein complexes, Biochemistry, 32 (1993) 2916-2922.
70. [70] G. Jori and E. Reddi, The role of lipoproteins in the delivery of tumour-targeting photosensitizers, Int. J. Biochem., 25 (1993) 1369-1375.
71. [71] J. Leppala, M. Kallio, T. Nikula, P. Nikkinen, K. Liewendahl, J. Jaaskelainen, S. Savolainen, H. Gylling, J. Hiltunen and M. Callaway, Accumulation of 99m-Tc low density lipoprotein in human malignant glioma, Br. J. Cancer, 71 (1995) 383-387.
72. [72] M.B. Lopes, C.A. Bogaev, S.L. Gonias and S.R. VandenBerg, Expression of alpha-2 macroglobulin receptor/ low density lipoprotein receptor related protein is increased in reactive and neoplastic glial cells, FEBS Lett., 338 (1994) 301-305.
73. [73] M.C. Luna, A. Ferrario, N. Rucker and C.J. Gomer, Decreased expression and function of alpha-2 macroglobulin receptor/low density lipoprotein receptor-related protein in photodynamic therapy-resistant mouse tumour cells, Cancer Res., 55 (9) (1995) 1820-1823.
74. [74] X.Y. He, R.A. Sikes, S. Thomsen, L.W. Chung and S. Jacques, Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines, Photochem. Photobiol., 59 (1994) 468-473.
75. [75] M.A. Laukka, K.K. Wang and J.A. Bonner, Apoptosis occurs in lymphoma cells but not in hepatoma cells following ionizing radiation and photodynamic therapy, Dig. Dis. Sci., 39 (1994) 2467-2475.
76. [76] S.I. Zaidi, N.L. Oleinick, M.T. Zaim and H. Mukhtar, Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumours in C3H mice: electron microscopic, histopathologic and biochemical evidence, Photochem. Photobiol., 58 (1993) 771-776.
77. [77] K. Konig, H. Schneckenburger, A. Ruck and R. Steiner, In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins, J. Photochem. Photobiol. B: Biol., 18 (1993) 287-290.
78. [78] Y. Ji, S.K. Powers, J.B. Brown, D. Walstad and L. Maliner, Toxicity of photodynamic therapy with photofrin in the normal rat brain, Lasers Surg. Med., 14 (1994) 219-228.
79. [79] Y. Yoshida, M.O. Dereski, J.H. Garcia, F.W. Hetzel and M. Chopp, Neuronal injury after photoactivation of photofrin II, Am. J. Pathol., 141 (1992) 989-997.
80. [80] Q. Chen, B.C. Wilson, M.O. Dereski, M.S. Patterson, M. Chopp and F.W. Hetzel, Effects of light beam size on fluence distribution and depth of necrosis in superficially applied photodynamic therapy of normal rat brain, Photochem. Photobiol., 56 (1992) 379-384.
81. [81] M.O. Dereski, L. Madigan and M. Chopp, The effect of hypothermia and hyperthermia on photodynamic therapy of normal brain, Neurosurgery, 36 (1995) 141-146.
82. [82] M.O. Dereski, M. Chopp, J.H. Garcia and F.W. Hetzel, Depth measurements and histopathological characterization of photodynamic therapy generated normal brain necrosis as a function of incident optical energy dose, Photochem. Photobiol., 54 (1991) 109-112.
83. [83] W. Stummer, C. Götz, A. Hassan, D.V.M. Heimann and O. Kempski, Kinetics of Photofrin II in perifocal brain oedema, Neurosurgery, 33 (1993) 1075-1082.
84. [84] M.K. Loeken, The effect of roentgen rays on several biological systems with special reference to their modification by hematoporphyrin, Ph.D. Thesis, University of Minnesota, 1956.
85. [85] K.T. Chen, D.M. Hau, J.S. You, H.C. Pan and R.W. Wong, Therapeutic effects of photosensitizers in combination with laser and ACNU on an in vivo or in vitro model of cerebral glioma, Chin. Med. J. Engl., 108 (1995) 98-104.
86. [86] M.L. Jin, B.Q. Yang, W. Zhang and P. Ren, Combined treatment with photodynamic therapy and chemotherapy for advanced cardiac cancers, J. Photochem. Photobiol. B: Biol., 12 (1992) 101-106.
87. [87] M.Y. Nahabedian, R.A. Cohen, M.F. Contino, T.M. Terem, W.H. Wright, M.W. Berns and A.G. Wile, Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumours, J. Natl. Cancer Inst., 80 (1988) 739-743.
88. [88] L.W. Ma, J. Moan, H.B. Steen and V. Iani, Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma, Br. J. Cancer, 71 (1995) 950-956.
89. [89] H.T. Whelan, L.H. Kras, K. Ozker, D. Bajic, M.H. Schmidt, Y. Liu, L.A. Trembath, F. Uzum, G.A. Meyer and A.D. Segura, Selective incorporation of 111In-labeled PHOTOFRIN by glioma tissue in vivo, J. Neurooncol., 22 (1994) 7-13.
90. [90] H. Kostron, personal observation, 1996.
91. [91] P.A. Cowled, L. Mackenzie and I.J. Forbes, Potentiation of photodynamic therapy with haematoporphyrin derivatives by glucocorticoids, Cancer Lett., 29 (1985) 107-114.
92. [92] H.W. Pogrebniak, W. Matthews, C. Black, A. Russo, J.B. Mitchell, P. Smith, J.A. Roth and H.I. Pass, Targeted phototherapy with sensitizer-monoclonal antibody conjugate and light, Surg. Oncol., 2 (1993) 31-42.
93. [93] K. Rittenhouse-Diakun, H. Van-Leegoed, J. Morgan, E. Hryhorenko, G. Paszkiewicz, J.F. Whitaker and A.R. Oseroff, The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA), Photochem. Photobiol., 61 (1995) 523-528.
94. [94] R.M. Rerko, M.E. Clay, A.R. Antunez, N.L. Oleinick and H.H. Evans, Photofrin II photosensitization is mutagenic at the tk locus in mouse L5187Y cells, Photochem. Photobiol., 55 (1992) 75-80.
95. [95] M. Dellinger, G. Moreno, C. Salet, H. Tapiero and T.J. Lampidis, Cytotoxic and photodynamic effects of Photofrin on sensitive and multi-drug-resistant Friend leukaemia cells, Int. J. Radiat. Biol., 62 (1992) 735-741.
96. [96] D. Kessel and C. Erickson, Porphyrin photosensitization of multi-drug resistant cell types, Photochem. Photobiol., 55 (1992) 397-399.
97. [97] R.A. Moorehead, S.G. Armstrong, B.C. Wilson and G. Singh, Cross resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy, Cancer Res., 54 (1994) 2556-2559.
98. [98] N.M. Bleehen and J.M. Ford, Radiotherapy, hyperthermia, and photodynamic therapy for central nervous system tumours, Curr. Opin. Oncol., 5 (1993) 458-463.
99. [99] M.S. Mahaley, Jr., Neuro-oncology index and review (adult primary brain tumours). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy, J. Neurooncol., 11 (1991) 85-147.
100. [100] T. Patrice, The combination of PDT and hyperthermia is a promising method for tumour treatment. Challenges for photodynamic therapy in the treatment of gastrointestinal tumours, J. Photochem. Photobiol. B: Biol., 9 (1991) 372-374.
101. [101] C. Prinsze, L.C. Penning, T.M. Dubbelmann and J. VanSteveninck, Interaction of photodynamic treatment and either hyperthermia or ionizing radiation and of ionizing radiation and hyperthermia with respect to cell killing of L929 fibroblasts, Chinese hamster ovary cells, and T24 human bladder carcinoma cells, Cancer Res., 52 (1992) 117-120.
102. [102] S.M. Waldow, B. Henderson and T.J. Dougherty, Potentiation of photodynamic therapy by heat: effect of sequence and time interval between treatments in vivo, Lasers Surg. Med., 5 (1988) 83-94.
103. [103] D.E. Bellnier and T. Dougherty, Haematoporphyrin derivative photosensitization and gamma-radiation damage interaction in Chinese hamster ovary fibroblasts, Int. J. Radiat. Biol., 50 (1986) 659-664.
104. [104] J. Winther, J. Overgaard and N. Ehlers, The effect of photodynamic therapy alone and in combination with misonidazole or X-rays for management of a retinoblastoma-like tumour, Photochem. Photobiol., 447 (1988) 419-423.
105. [105] H. Kostron, M.R. Swartz, D.C. Miller and R.L. Martuza, The interaction of hematoporphyrin derivative, light and ionizing radiation in a rat glioma model, Cancer, 57 (1986) 964-970.
106. [106] Y. Layat and T. Patrice, personal communication, Year, 1995.
107. [107] E.R. Laws, Jr., D.A. Cortese, J.H. Kinsey, R.T. Eagan and R.E. Anderson, Photoradiation therapy in the treatment of malignant tumours. A phase I (feasibility study), Neurosurgery, 9 (1981) 672-678.
108. [108] R.E. Wharren Jr., R.E. Anderson and E.R. Laws, Jr., Quantitation of hematoporphyrin derivative in human gliomas, experimental central nervous tumours and normal tissue, Neurosurgery, 12 (1983) 446-450.
109. [109] G.A. McCulloch, I.J. Forbes, K.L. See, P.A. Cowled, F.J. Jacka and A.D. Ward, Phototherapy in malignant brain tumors, in D.R. Doiron (ed.), Porphrin localisation and treatment of tumours, A.R. Liss, New York, 1984, pp. 709-717.
110. [110] P.J. Muller and B.C. Wilson, The use of photodynamic therapy for recurrent gliomas, 5th International Photodynamic Association Biennial Meeting, Amelia Island, Florida, International Photodynamic Association, Matrix Meeting, Inc., Rochester, MN, Abstract 52.
111. [111] P.V. Marks, C. Fourneaux and R. Shivvakumar, An in vitro study of the effect of photodynamic therapy on human meningiomas, Br. J. Neurosurg., 6 (1992) 327-322.
112. [112] S. Kimel, L.O. Svaasand, M. Hammer-Wilson, V. Gottfried, S. Cheng, E. Svaasand and M.W. Berns, Demonstration of synergistic effects of hyperthermia and photodynamic therapy using the chick chorioallantoic membrane model, Lasers Surg. Med., 12 (1992) 432-440.
113. [113] A. Benzer, C. Putensen and H. Kostron, Photodynamic therapy [letter], Lancet, 2 (1989) 382-383.
114. [114] H.T. Whelan, M.H. Schmidt, A.D. Segura, T.L. McAuliffe, D.M. Bajic, K.J. Murray, J.E. Moulder, D.R. Strother, J.P. Thomas and G.A. Meyer, The role of photodynamic therapy in posterior fossa brain tumours. A preclinical study in a canine glioma model, J. Neurosurg., 79 (1993) 562-568.
115. [115] B.A. Goff, U. Hermato, J. Rumbaugh, J. Blake, M. Banberg and T. Hasan, Photoimmunotherapy and biodistribution with an OC125-chlorine immunoconjugate in an in vivo murine ovarian cancer model, Br. J. Cancer, 70 (1994) 474-480.